Intercell's Japanese Encephalitis vaccine safe in Phase III trials
16-Jan-2006
Completion of recruitment for the pivotal safety and the pivotal immunogenicity trial is expected early this year. Results of these Phase III trials are expected in mid 2006. First license applications will be made in the US, EU and Australia.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Cobra Biologics and Algeta Sign Agreement to Manufacture Monoclonal Antibody
Go to page
List_of_lymantriid_genera:I
Go to page
Celsius® FT100 | Freezing systems | Sartorius
Go to page
List_of_arctiid_genera:_I
Go to page
List_of_hesperiid_genera:X
Go to page
Diazepam
Go to page
List_of_gelechiid_genera:_X
Go to page
Dexamethasone
Go to page
List_of_lycaenid_genera:_T
Go to page
Successful FDA Inspection at Gerresheimer Medical Plastic Systems Dongguan in China
Go to page
Algeta and Sanofi extend research collaboration evaluating thorium-conjugated tumor-targeting antibody
Go to page
Oxford BioMedica: Management and Board change - Appointment of new Chief Financial Officer and Company Secretary
Go to page